期刊
FRONTIERS IN IMMUNOLOGY
卷 7, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2016.00589
关键词
IgG; rhesus; effector function; non-human primate; Fc receptor
类别
资金
- Collaboration for AIDS Vaccine Discovery [OPP1032817, OPP1114729]
- NIH [5R01AI102691, P01AI120758, AI097315, OD010976]
- NIH/NIAID Reagent Resource Support Program for AIDS Vaccine Development (Quality Biological, Inc.) [HHSN272201100023C]
- Center for HIV-AIDS Vaccine Immunology-Immunogen Design (CHAVI-ID) grant [AI100645]
- NIAID [HHSN272201300031C]
Antibodies raised in Indian rhesus macaques [Macaca mulatta (MM)] in many preclinical vaccine studies are often evaluated in vitro for titer, antigen-recognition breadth, neutralization potency, and/or effector function, and in vivo for potential associations with protection. However, despite reliance on this key animal model in translation of promising candidate vaccines for evaluation in first in man studies, little is known about the properties of MM immunoglobulin G (IgG) subclasses and how they may compare to human IgG subclasses. Here, we evaluate the binding of MM IgG1, IgG2, IgG3, and IgG4 to human Fc gamma receptors (Fc gamma R) and their ability to elicit the effector functions of human Fc gamma R-bearing cells, and unlike in humans, find a notable absence of subclasses with dramatically silent Fc regions. Biophysical, in vitro, and in vivo characterization revealed MM IgG1 exhibited the greatest effector function activity followed by IgG2 and then IgG3/4. These findings in rhesus are in contrast with the canonical understanding that IgG1 and IgG3 dominate effector function in humans, indicating that subclass-switching profiles observed in rhesus studies may not strictly recapitulate those observed in human vaccine studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据